Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

One Wales Medicines Assessment Group Recommendation
Gilteritinib film-coated tablets

Date of advice: November 2026
AWTTC reference number: OW36

It is the view of the One Wales Medicines Assessment Group (OWMAG) that gilteritinib should not be supported within NHS Wales for maintenance therapy after haematopoietic stem cell transplant for acute myeloid leukaemia in adults with FLT3-ITD mutation and evidence of measurable residual disease before or after transplant.

Individual Patient Funding Request (IPFR) consideration remains appropriate for those patients who are likely to obtain significantly more clinical benefit from the intervention than would normally be expected at a reasonable value for money.

This recommendation has been endorsed by the All Wales Medicines Strategy Group (AWMSG) and ratified by Welsh Government.

This advice will be reviewed after 12 months or earlier if new evidence becomes available.

One Wales advice assists consistency of access across NHS Wales.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group Recommendation (OW36): Off-label gilteritinib for maintenance therapy after haematopoietic stem cell transplant for acute myeloid leukaemia in adults with FLT3-ITD mutation and evidence of measurable residual disease before or after transplant indication. December 2026.

AWTTC
All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan